Quarterly report [Sections 13 or 15(d)]

Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - Twist Bioscience (Details)

v3.25.1
Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - Twist Bioscience (Details)
$ in Thousands
 1 Months Ended 3 Months Ended
Oct. 31, 2024
USD ($)
item
Program
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2024
USD ($)
Agreements        
Payments of consideration under RPAs, AAAs and CPPAs   $ 8,000 $ 15,000  
Long-term royalty and commercial payment receivables under the cost recovery method   59,916   $ 55,936
Short-term royalty and commercial payment receivables under the cost recovery method   413   413
Royalty Purchase Agreement | Twist        
Agreements        
Contingent payments acquired (as a percent) 50.00%      
Payments of consideration under RPAs, AAAs and CPPAs $ 15,000      
Maximum milestone payments entitled to receive $ 500,000      
Royalties entity has right to receive (as a percent) 50.00%      
Long-term royalty and commercial payment receivables under the cost recovery method $ 15,000      
Short-term royalty and commercial payment receivables under the cost recovery method   0    
Allowance for credit losses   $ 0   $ 0
Royalty Purchase Agreement | Twist | Minimum        
Agreements        
Number of early-stage programs | Program 60      
Number of partners associated with programs | item 30